FRAME SHIFT BIO-INCUBATOR

The Milner Therapeutics Institute provides space for start-ups and SMEs through the Frame Shift Bio-incubator.

Frame Shift provides a unique environment for companies to work side-by-side with startups, pharma and academic scientists in an ecosystem physically and culturally designed to spark collaboration and entrepreneurship. Frame Shift has a particular focus on R&D intensive companies working in areas related to the institute’s expertise (e.g. functional genomics, early target discovery, therapeutics). Frame Shift complements other programmes such as the Start Codon Accelerator, providing flexible options for start-up companies at different stages in their development.

Frame Shift began with the successful model of companies such as Rockend Ltd (now Xap Therapeutics) who have been located in the institute during the past two years and have now expanded significantly as to require expansion to another site. Companies in the incubator will have access to space in the MTI environment for 12 months to conduct critical R&D work and successfully grow so that they are ready to scale-up at one of the science parks in Cambridge.

Benefits for companies in the Frame Shift Bio-incubator include:

  • Potential for interactions with clinicians, researchers and drug discovery scientists at the University and hospitals on the biomedical campus.
  • Advice and research input from the Milner Centre of Pathway Analysis
  • Know-how and expertise of representatives of the eleven Milner affiliated pharma companies that are part of our Consortium
  • Membership of an exclusive network of 70+ affiliated global pharma and biotech companies, and access to Milner internal and external events, including the annual Milner Therapeutics Symposium

You can read more about our Frame Shift companies below. For further information on space in the bio-incubator, please email contact@milner.cam.ac.uk.

Frame Shift Companies

 

ENHANC3D GENOMICS

Enhanc3D Genomics is a functional genomics spinout company from the Babraham Institute, leveraging a disruptive technology to profile three-dimensional (3D) genome folding at high resolution. Understanding DNA organisation and long-distance interactions allows to link gene enhancers and non-coding genetic variants to their target genes and holds promise to unlock disease-related genetics for therapeutic discovery. Debora Lucarelli is Enhanc3D Genomics’ CEO and has a keen interest in disruptive technologies that have potential to benefit human healthcare.

Contact Debora by emailing dlucarelli@enhanc3dgenomics.com


Debora Lucarelli

EPITOPEA

Epitopea is a new transatlantic cancer-immunotherapeutics company with operations in Cambridge and Montreal. The company builds on the recent discovery of an abundant new class of tumour-specific antigen. The company aims to discover additional antigens and prioritise the most promising for exploitation via multiple modalities to achieve our goal: guiding the adaptive immune system to control cancer.

Contact Jon by emailing Jon.Moore@Epitopea.com


Jon Moore

 

SHIFT BIOSCIENCE LTD

Shift Bioscience, cofounded by Daniel Ives, is developing safer drug targets for cellular rejuvenation by the application of machine-learning ‘driver’ clocks to cell reprogramming. Daniel (CEO) helped guide Brendan Swain (CSO) to develop an accurate single cell ageing clock, through the application of machine learning approaches to gene expression data. This enabled a CRISPR screen for ageing, but more excitingly, the constituent genes making up the clock were enriched for functional ‘drivers’ of ageing phenotypes, suggesting a causal or ‘driver’ clock methodology. This methodology was then applied to a powerful but dangerous cellular rejuvenation paradigm (cell reprogramming with pluripotent factors OSKM), which identified putative drug targets for safe rejuvenation. Shift is now on the cusp of validating these drug targets (more detail here).

Contact Daniel by emailing daniel@shiftbioscience.com


Daniel Ives

XAP THERAPEUTICS

Xap Therapeutics (formerly Rockend), co-founded by Dr James Patterson, is developing a next generation cell-based therapeutic. Their platform is based upon genetically engineered iPSCs, and makes use of multiple new advances across the synthetic biology and genome editing space.

Rockend Ltd aim to develop a non-immunogenic, intelligent and safe drug that could be used for the treatment of cancers, autoimmune diseases and various other unmet medical needs.

Contact James by emailing james.patterson@xaptherapeutics.com

 


James Patterson